이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Certolizumab Pegol의 소아 관절염 연구 (PASCAL)

2026년 9월 1일 업데이트: UCB BIOSCIENCES GmbH

중등도~중증 활동성 다관절 경과 소아 특발성 관절염(JIA)이 있는 소아 및 청소년에서 세르톨리주맙 페골의 약동학, 안전성 및 효능을 평가하기 위한 다기관 공개 라벨 연구

A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).

연구 개요

상세 설명

The overall study consists of a Screening Period of up to 4 weeks and an Open-Label Treatment Period which will continue until the approval of the marketing application for the Polyarticular-course Juvenile Idiopathic Arthritis (JIA) indication in the study participant's country or region or until further notice from UCB (approximately 4-6 years duration; depending on region). A Final Visit will be conducted 12 weeks after last dose of study medication. Overall, study visits will occur monthly during the first 6 months and every 2 months afterwards. All patients will receive active treatment with Certolizumab Pegol. The dose will depend on actual weight. Home dosing will be allowed between study visits.

If less than 50 % of the study population achieves an adequate response to the treatment (American College of Rheumatology Pediatric 30 % (PedACR30) response) at Week 16, the study will be entirely discontinued.

연구 유형

중재적

등록 (실제)

193

단계

  • 3단계

확장된 액세스

더 이상 사용할 수 없음 임상시험 외. 확장 액세스 기록을 참조하세요.

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Moscow, 러시아 제국
        • Ra0043 41
      • Moscow, 러시아 제국
        • Ra0043 43
      • Saint Petersburg, 러시아 제국
        • Ra0043 40
      • Tolyatti, 러시아 제국
        • Ra0043 42
      • Mexico City, 멕시코
        • Ra0043 32
      • Monterrey, 멕시코
        • Ra0043 30
      • México, 멕시코
        • Ra0043 31
      • San Luis Potosí City, 멕시코
        • Ra0043 33
    • Arkansas
      • Little Rock, Arkansas, 미국, 72202
        • Ra0043 71
    • California
      • Los Angeles, California, 미국, 90027-6062
        • Ra0043 79
      • San Francisco, California, 미국, 94143
        • Ra0043 84
    • Connecticut
      • Hartford, Connecticut, 미국, 06106
        • Ra0043 83
    • District of Columbia
      • Washington D.C., District of Columbia, 미국, 20010
        • Ra0043 81
    • Illinois
      • Chicago, Illinois, 미국, 60611
        • Ra0043 82
      • Chicago, Illinois, 미국, 60637
        • Ra0043 90
    • Indiana
      • Indianapolis, Indiana, 미국, 46202
        • Ra0043 75
    • New Jersey
      • Hackensack, New Jersey, 미국, 07601
        • Ra0043 80
      • Livingston, New Jersey, 미국, 07039
        • Ra0043 77
    • New York
      • New Hyde Park, New York, 미국, 11042
        • Ra0043 85
      • New York, New York, 미국, 10032
        • Ra0043 87
    • North Carolina
      • Charlotte, North Carolina, 미국, 28203
        • Ra0043 74
      • Durham, North Carolina, 미국, 27710
        • Ra0043 76
    • Ohio
      • Avon, Ohio, 미국, 44011
        • Ra0043 70
      • Cincinnati, Ohio, 미국, 45229
        • Ra0043 73
      • Cleveland, Ohio, 미국, 44109
        • Ra0043 78
      • Cleveland, Ohio, 미국, 44195
        • Ra0043 95
      • Columbus, Ohio, 미국, 43205-2694
        • Ra0043 86
    • Oregon
      • Portland, Oregon, 미국, 97227
        • Ra0043 89
      • Curitiba, 브라질
        • Ra0043 15
      • Porto Alegre, 브라질
        • Ra0043 14
      • São Paulo, 브라질
        • Ra0043 12
      • Buenos Aires, 아르헨티나
        • RA0043 2
      • Santiago, 칠레
        • Ra0043 60
      • Calgary, 캐나다
        • Ra0043 21
      • Montreal, 캐나다
        • Ra0043 22
      • Toronto, 캐나다
        • Ra0043 20

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

2년 (어린이)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Study participant is 2 to 17 years of age (inclusive) at Baseline (Visit 2)
  • Study participants must weigh ≥10 kg (22lb) at Baseline (Visit 2)
  • Study participants must have had onset of signs and symptoms consistent with a diagnosis of Juvenile Idiopathic Arthritis (JIA) (according to the International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis, 2001) and initiation of JIA treatment for at least 6 months prior to Baseline (Visit 2). Eligible JIA categories include: polyarthritis rheumatoid factor-positive, polyarthritis rheumatoid factor-negative, extended oligoarthritis, juvenile psoriatic arthritis, and enthesitis-related arthritis (ERA)
  • Study participants must have active polyarticular-course disease, defined as ≥5 joints with active arthritis at Screening and at Baseline
  • Study participants must have had an inadequate response to, or intolerance to, at least 1 disease-modifying antirheumatic drug (DMARD) (nonbiologic or biologic). For example, study participant had prior inadequate response to methotrexate (MTX) (based on the Investigator's clinical judgment)
  • If the study participant is using MTX, then the study participant must have been on MTX for a minimum of 3 months at Screening. In addition, the dose must have been stable for at least 1 month before Screening at ≥10 to ≤15 mg/m^2 per week. If the study participant is not using MTX, then the treatment must have been previously withdrawn for documented reasons of intolerability or inadequate response
  • If the study participant is using oral corticosteroid therapy, the dose must have been stable for at least 7 days prior to the Baseline arthritis assessment at a maximum dose of 10 mg or 0.2 mg/kg prednisone (or equivalent) per day, whichever is the smaller dose

Exclusion Criteria:

  • Study participant has previously been exposed to more than 2 biologic agents
  • Study participant previously failed to respond to treatment with more than one tumor necrosis factor alpha (TNFα) antagonist drug
  • Study participant is currently receiving or has received any experimental (biological or nonbiological) therapy (within or outside a clinical study) in the 3 months or 5 half-lives prior to Baseline (Visit 2), whichever is longer
  • Study participant had previous treatment with a biological therapy for juvenile idiopathic arthritis (JIA) that resulted in a severe hypersensitivity reaction or an anaphylactic reaction
  • Study participant previously participated in this study or has previously been treated with CZP (whether in a study or not)
  • Study participant has a history of systemic JIA, with or without systemic features
  • Study participant has a secondary, noninflammatory type of rheumatic disease or of joint pains (eg, fibromyalgia) that in the Investigator's opinion is symptomatic enough to interfere with evaluation of the effect of study medication
  • Study participant has other inflammatory arthritis (eg, systemic lupus erythematosus, inflammatory bowel disease-related)
  • Study participant has active uveitis or a history of active uveitis within the preceding 6 months
  • Study participant has current, chronic or recurrent clinically significant infections
  • Study participant has a current sign or symptom which may indicate infection (eg, fever, cough), a history of chronic or recurrent infections within the same organ system (more than 3 episodes requiring antibiotics/antivirals during the 12 months prior to Screening [Visit 1]), had a recent (within the 6 months prior to Screening [Visit 1]) serious or life-threatening infection (including herpes zoster), or is at a high risk of infection in the Investigator's opinion (eg, study participants with leg ulcers, indwelling urinary catheter, and persistent or recurrent chest infections or permanently bed-ridden or wheelchair bound)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Certolizumab Pegol

Active treatment with Certolizumab Pegol; dose adjustment is based on weight.

CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.

CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.

Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.

Reduced CZP regimen (after implementation of protocol amendments 4 and 5):

  • 10 to < 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);
  • 20 to < 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);
  • ≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);
다른 이름들:
  • 심지아

CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.

CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.

Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.

Original CZP regimen (prior to implementation of protocol amendments 4 and 5 and after implementation of protocol amendment 9):

  • 10 to < 20 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);
  • 20 to < 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc,); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);
  • ≥ 40 kg: Loading dose = 400 mg Q2W (2 x 1.0 mL sc); treatment dose = 200 mg Q2W (1 x 1.0 mL sc);
다른 이름들:
  • 심지아

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16
기간: Week 16

Certolizumab Pegol (CZP) plasma concentration level was measured in micrograms per milliliter (ug/ml).

Week 16
Certolizumab Pegol (CZP) Plasma Concentration Level at Week 48
기간: Week 48

Certolizumab Pegol (CZP) plasma concentration level was measured in ug/mL.

Week 48
Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 16
기간: Week 16

Number of participants with anti-CZP antibodies were reported.

Week 16
Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 48
기간: Week 48

Number of participants with anti-CZP antibodies were reported.

Week 48
Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the Study
기간: From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)

A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: results in deaths, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect and other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. TEAEs are defined as AEs starting on or after first administration of CZP and up to 70 days after last dose of study medication.

From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of the Investigational Medicinal Product (IMP) During the Study
기간: From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)

An AE is any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an IMP, whether or not related to the IMP. TEAEs are defined as AEs starting on or after first administration of CZP and up to 70 days after last dose of study medication. TEAEs leading to permanent withdrawal of the IMP during the study were reported in this outcome measure.

From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)

2차 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants Meeting American College of Rheumatology Pediatric 30 % (PedACR30) Response Criteria at Week 16
기간: Week 16

PedACR30-at least 30% improvement from baseline in 3 of any 6 core set measures, with no more than 1 of remaining variables worsening by >30%:

  • Number of joints with active arthritis
  • Number of joints with limitation of range of motion
  • Physician's Global Assessment of Disease Activity (using visual analog scale (VAS): 100mm; 0= very good, and 100= very poor)
  • CHAQ (30 questions, 8 domains, scores for each domain are averaged to calculate total score [ 0= no disability to 3= very severe disability])
  • Parent's Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor)
  • C-reactive protein (CRP)
Week 16
Percentage of Participants Meeting American College of Rheumatology Pediatric 50 % (PedACR50) Response Criteria at Week 16
기간: Week 16

PedACR50- at least 50% improvement from baseline in 3 of any 6 core set measures, with no more than 1 of remaining variables worsening by >30%:

  • Number of joints with active arthritis
  • Number of joints with limitation of range of motion
  • Physician's Global Assessment (PGA) of Disease Activity (using VAS: 100mm; 0= very good, and 100= very poor)
  • Childhood Health Assessment Questionnaire (CHAQ) (30 questions, 8 domains, scores for each domain are averaged to calculate total score [ 0= no disability to 3= very severe disability])
  • Parent's Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor)
  • CRP
Week 16
Percentage of Participants Meeting American College of Rheumatology Pediatric 70 % (PedACR70) Response Criteria at Week 16
기간: Week 16

PedACR70- at least 70% improvement from baseline in 3 of any 6 following core set measures, with no more than 1 of remaining variables worsening by >30%:

  • Number of joints with active arthritis
  • Number of joints with limitation of range of motion
  • Physician's Global Assessment of Disease Activity (using VAS: 100mm; 0= very good, and 100= very poor)
  • CHAQ (30 questions, 8 domains, scores for each domain are averaged to calculate total score [ 0= no disability to 3= very severe disability])
  • Parent's Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor)
  • CRP
Week 16
Percentage of Participants Meeting American College of Rheumatology Pediatric 90 % (PedACR90) Response Criteria at Week 16
기간: Week 16

PedACR90- at least 90% improvement from baseline in 3 of any 6 following core set measures, with no more than 1 of remaining variables worsening by >30%:

  • Number of joints with active arthritis
  • Number of joints with limitation of range of motion
  • Physician's Global Assessment of Disease Activity (using VAS: 100mm; 0= very good, and 100= very poor)
  • CHAQ (30 questions, 8 domains, scores for each domain are averaged to calculate total score [ 0= no disability to 3= very severe disability])
  • Parent's Global Assessment of Overall Well-Being (using VAS: 100mm; 0= Very well to 100= Very poor)
  • CRP
Week 16

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: UCB Cares, 001 844 599 2273 (UCB)

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2012년 3월 8일

기본 완료 (실제)

2024년 4월 8일

연구 완료 (실제)

2024년 4월 8일

연구 등록 날짜

최초 제출

2012년 3월 7일

QC 기준을 충족하는 최초 제출

2012년 3월 7일

처음 게시됨 (추정된)

2012년 3월 9일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 25일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 1일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

IPD 공유 기간

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

IPD 공유 액세스 기준

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • CSR

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다